{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:55:50Z","timestamp":1789656950066,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,22]],"date-time":"2017-07-22T00:00:00Z","timestamp":1500681600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11060-017-2567-9","type":"journal-article","created":{"date-parts":[[2017,7,22]],"date-time":"2017-07-22T10:46:30Z","timestamp":1500720390000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma"],"prefix":"10.1007","volume":"135","author":[{"given":"Iddo","family":"Paldor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Abbadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto J.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rowshanshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MariaLisa","family":"Itzoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Vigilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Brem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-6969","authenticated-orcid":false,"given":"Betty M.","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,22]]},"reference":[{"key":"2567_CR1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/B978-0-444-52902-2.00054-0","volume":"115","author":"SK Lloyd","year":"2013","unstructured":"Lloyd SK, Evans DG (2013) Neurofibromatosis type 2 (NF2): diagnosis and management. Handb Clin Neurol 115:957\u2013967","journal-title":"Handb Clin Neurol"},{"key":"2567_CR2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"DG Evans","year":"2009","unstructured":"Evans DG (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4:16","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2567_CR3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138920310791824011","volume":"11","author":"I Stamenkovic","year":"2010","unstructured":"Stamenkovic I, Yu Q (2010) Merlin, a \u201cmagic\u201d linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Current Protein Pept Sci 11(6):471\u2013484","journal-title":"Current Protein Pept Sci"},{"issue":"29","key":"2567_CR4","doi-asserted-by":"crossref","first-page":"30265","DOI":"10.1074\/jbc.M312083200","volume":"279","author":"JY Lee","year":"2004","unstructured":"Lee JY, Kim H, Ryu CH et al (2004) Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity. J Biol Chem 279(29):30265\u201330273","journal-title":"J Biol Chem"},{"issue":"1","key":"2567_CR5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ncb1339","volume":"8","author":"F Hamaratoglu","year":"2006","unstructured":"Hamaratoglu F, Willecke M, Kango-Singh M et al (2006) The tumour-suppressor genes NF2\/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 8(1):27\u201336","journal-title":"Nat Cell Biol"},{"issue":"2","key":"2567_CR6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1593\/neo.111600","volume":"14","author":"HK Wong","year":"2012","unstructured":"Wong HK, Shimizu A, Kirkpatrick ND et al (2012) Merlin\/NF2 regulates angiogenesis in schwannomas through a Rac1\/semaphorin 3F-dependent mechanism. Neoplasia 14(2):84\u201394","journal-title":"Neoplasia"},{"issue":"1","key":"2567_CR7","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MAO.0000000000000239","volume":"35","author":"SR Plotkin","year":"2014","unstructured":"Plotkin SR, Merker VL, Muzikansky A, Barker FG 2nd, Slattery W 3rd (2014) Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol 35(1):e50\u2013e56","journal-title":"Otol Neurotol"},{"key":"2567_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2016.05.003","volume":"32","author":"I Paldor","year":"2016","unstructured":"Paldor I, Chen AS, Kaye AH (2016) Growth rate of vestibular schwannoma. J Clin Neurosci 32:1\u20138. doi: 10.1016\/j.jocn.2016.05.003","journal-title":"J Clin Neurosci"},{"issue":"1","key":"2567_CR9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3171\/2011.8.JNS11215","volume":"116","author":"M Elsharkawy","year":"2012","unstructured":"Elsharkawy M, Xu Z, Schlesinger D, Sheehan JP (2012) Gamma Knife surgery for nonvestibular schwannomas: radiological and clinical outcomes. J Neurosurg 116(1):66\u201372","journal-title":"J Neurosurg"},{"issue":"14","key":"2567_CR10","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG et al (2016) Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J Clin Oncol 34(14):1669\u20131675","journal-title":"J Clin Oncol"},{"issue":"4","key":"2567_CR11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hoc.2011.04.008","volume":"25","author":"MH Voss","year":"2011","unstructured":"Voss MH, Molina AM, Motzer RJ (2011) mTOR inhibitors in advanced renal cell carcinoma. Hematol\/Oncol Clin North Am 25(4):835\u2013852","journal-title":"Hematol\/Oncol Clin North Am"},{"issue":"2","key":"2567_CR12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000354754","volume":"6","author":"PJ Fonseca","year":"2013","unstructured":"Fonseca PJ, Uriol E, Galvan JA et al (2013) Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma. Case Rep Oncol 6(2):441\u2013449","journal-title":"Case Rep Oncol"},{"issue":"10","key":"2567_CR13","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/annonc\/mds075","volume":"23","author":"C Villarreal-Garza","year":"2012","unstructured":"Villarreal-Garza C, Cortes J, Andre F, Verma S (2012) mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. Ann Oncol 23(10):2526\u20132535","journal-title":"Ann Oncol"},{"issue":"5","key":"2567_CR14","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1535-7163.MCT-07-2335","volume":"7","author":"G Johansson","year":"2008","unstructured":"Johansson G, Mahller YY, Collins MH et al (2008) Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 7(5):1237\u20131245","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2567_CR15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/neuonc\/not242","volume":"16","author":"M Giovannini","year":"2014","unstructured":"Giovannini M, Bonne NX, Vitte J et al (2014) mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol 16(4):493\u2013504","journal-title":"Neuro Oncol"},{"issue":"2","key":"2567_CR16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Hagiwara M et al (2014) Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 16(2):292\u2013297","journal-title":"Neuro Oncol"},{"issue":"2","key":"2567_CR17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny S, Raymond E, Esposito-Farese M et al (2015) Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 122(2):313\u2013320","journal-title":"J Neurooncol"},{"issue":"10","key":"2567_CR18","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2013.51.4737","volume":"32","author":"V Guarneri","year":"2014","unstructured":"Guarneri V, Generali DG, Frassoldati A et al (2014) Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. J Clin Oncol 32(10):1050\u20131057","journal-title":"J Clin Oncol"},{"issue":"8","key":"2567_CR19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/neuonc\/noq012","volume":"12","author":"S Ammoun","year":"2010","unstructured":"Ammoun S, Cunliffe CH, Allen JC et al (2010) ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol 12(8):834\u2013843","journal-title":"Neuro Oncol"},{"issue":"5","key":"2567_CR20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/MAO.0b013e31821f7d88","volume":"32","author":"ZK Ahmad","year":"2011","unstructured":"Ahmad ZK, Brown CM, Cueva RA, Ryan AF, Doherty JK (2011) ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas. Otol Neurotol 32(5):841\u2013847","journal-title":"Otol Neurotol"},{"issue":"9","key":"2567_CR21","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","volume":"14","author":"MA Karajannis","year":"2012","unstructured":"Karajannis MA, Legault G, Hagiwara M et al (2012) Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 14(9):1163\u20131170","journal-title":"Neuro Oncol"},{"issue":"5","key":"2567_CR22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","volume":"89","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian H (2014) Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 89(5):547\u2013556","journal-title":"Am J Hematol"},{"issue":"4","key":"2567_CR23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00280-011-1785-7","volume":"69","author":"C Cauchi","year":"2012","unstructured":"Cauchi C, Somaiah N, Engstrom PF et al (2012) Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol 69(4):977\u2013982","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2567_CR24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/neuonc\/nor056","volume":"13","author":"S Ammoun","year":"2011","unstructured":"Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO (2011) Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol 13(7):759\u2013766","journal-title":"Neuro Oncol"},{"issue":"1","key":"2567_CR25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.a.34359","volume":"158A","author":"JO Blakeley","year":"2012","unstructured":"Blakeley JO, Evans DG, Adler J et al (2012) Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet Part A 158A(1):24\u201341","journal-title":"Am J Med Genet Part A"},{"issue":"2","key":"2567_CR26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/01677060009083477","volume":"14","author":"DJ Lim","year":"2000","unstructured":"Lim DJ, Rubenstein AE, Evans DG et al (2000) Advances in neurofibromatosis 2 (NF2): a workshop report. J Neurogenet 14(2):63\u2013106","journal-title":"J Neurogenet"},{"key":"2567_CR27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3171\/2014.7.GKS141311","volume":"121","author":"C Seferis","year":"2014","unstructured":"Seferis C, Torrens M, Paraskevopoulou C, Psichidis G (2014) Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate. J Neurosur 121:160\u2013166","journal-title":"J Neurosur"},{"key":"2567_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-017-1048-z","author":"I Vuletic","year":"2017","unstructured":"Vuletic I, Zhou K, Li H et al (2017) Validation of bevacizumab therapy effect on colon cancer subtypes by using whole body imaging in mice. Mol Imaging Biol. doi: 10.1007\/s11307-017-1048-z","journal-title":"Mol Imaging Biol"},{"issue":"2","key":"2567_CR29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.21873\/anticanres.11356","volume":"37","author":"N Ishikura","year":"2017","unstructured":"Ishikura N, Yanagisawa M, Noguchi-Sasaki M et al (2017) Importance of bevacizumab maintenance following combination chemotherapy in human non-small cell lung cancer xenograft models. Anticancer Res 37(2):623\u2013629","journal-title":"Anticancer Res"},{"issue":"2","key":"2567_CR30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10238-016-0409-2","volume":"17","author":"CJ Tai","year":"2017","unstructured":"Tai CJ, Wang H, Wang CK et al (2017) Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts. Clin Exp Med 17(2):141\u2013150","journal-title":"Clin Exp Med"},{"issue":"2","key":"2567_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-1759(97)00043-4","volume":"204","author":"GR Nakayama","year":"1997","unstructured":"Nakayama GR, Caton MC, Nova MP, Parandoosh Z (1997) Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J Immunol Methods 204(2):205\u2013208","journal-title":"J Immunol Methods"},{"issue":"5","key":"2567_CR32","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00280-013-2116-y","volume":"71","author":"DK Pawaskar","year":"2013","unstructured":"Pawaskar DK, Straubinger RM, Fetterly GJ et al (2013) Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. Cancer Chemother Pharmacol 71(5):1219\u20131229","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2567_CR33","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00280-013-2117-x","volume":"71","author":"DK Pawaskar","year":"2013","unstructured":"Pawaskar DK, Straubinger RM, Fetterly GJ et al (2013) Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol 71(5):1231\u20131240","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"2567_CR34","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/sj.bjc.6605076","volume":"100","author":"D Cejka","year":"2009","unstructured":"Cejka D, Kuntner C, Preusser M et al (2009) FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. Br J Cancer 100(11):1739\u20131745","journal-title":"Br J Cancer"},{"issue":"4","key":"2567_CR35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00280-009-1068-8","volume":"65","author":"T O\u2019Reilly","year":"2010","unstructured":"O\u2019Reilly T, McSheehy PM, Kawai R et al (2010) Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol 65(4):625\u2013639","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2567_CR36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00401-012-0954-z","volume":"123","author":"FJ Rodriguez","year":"2012","unstructured":"Rodriguez FJ, Folpe AL, Giannini C, Perry A (2012) Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol 123(3):295\u2013319","journal-title":"Acta Neuropathol"},{"issue":"11","key":"2567_CR37","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/jnnp.74.11.1536","volume":"74","author":"JG Rowe","year":"2003","unstructured":"Rowe JG, Radatz MW, Walton L, Hampshire A, Seaman S, Kemeny AA (2003) Gamma knife stereotactic radiosurgery for unilateral acoustic neuromas. J Neurol Neurosurg Psychiatry 74(11):1536\u20131542","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2567_CR38","doi-asserted-by":"crossref","first-page":"W646","DOI":"10.2214\/AJR.12.8577","volume":"200","author":"NA Koontz","year":"2013","unstructured":"Koontz NA, Wiens AL, Agarwal A et al (2013) SChwannomatosis: the overlooked neurofibromatosis? Am J Roentgenol 200(6):W646\u201353","journal-title":"Am J Roentgenol"},{"key":"2567_CR39","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000156907","volume":"21","author":"J Rowe","year":"2008","unstructured":"Rowe J, Radatz M, Kemeny A (2008) Radiosurgery for type II neurofibromatosis. Prog Neurol Surg 21:176\u2013182","journal-title":"Prog Neurol Surg"},{"issue":"47","key":"2567_CR40","doi-asserted-by":"publisher","first-page":"14676","DOI":"10.1073\/pnas.1512570112","volume":"112","author":"X Gao","year":"2015","unstructured":"Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, Selig MK, Plotkin SR, Jain RK, Xu L (2015) Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc Natl Acad Sci USA 112(47):14676\u201381. doi: 10.1073\/pnas.1512570112","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2567_CR41","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.neo.7900265","volume":"4","author":"SM Messerli","year":"2002","unstructured":"Messerli SM, Tang Y, Giovannini M, Bronson R, Weissleder R, Breakefield XO (2002) Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia 4(6):501\u2013509","journal-title":"Neoplasia"},{"issue":"1","key":"2567_CR42","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen WJ, Miller SJ, Jousma E et al (2013) MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 123(1):340\u2013347","journal-title":"J Clin Invest"},{"issue":"13","key":"2567_CR43","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","volume":"14","author":"M Giovannini","year":"2000","unstructured":"Giovannini M, Robanus-Maandag E, van der Valk M et al (2000) Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 14(13):1617\u20131630","journal-title":"Genes Dev"},{"issue":"1","key":"2567_CR44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/hum.2006.17.20","volume":"17","author":"SM Messerli","year":"2006","unstructured":"Messerli SM, Prabhakar S, Tang Y et al (2006) Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther 17(1):20\u201330","journal-title":"Hum Gene Ther"},{"issue":"14","key":"2567_CR45","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-12-3167","volume":"19","author":"K Tanaka","year":"2013","unstructured":"Tanaka K, Eskin A, Chareyre F et al (2013) Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clin Cancer Res 19(14):3856\u20133870","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2567_CR46","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-03-4079","volume":"64","author":"AO Stemmer-Rachamimov","year":"2004","unstructured":"Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, Schmale MC, MacCollin M, Chao RC, Cichowski K, Kalamarides M, Messerli SM, McClatchey AI, Niwa-Kawakita M, Ratner N, Reilly KM, Zhu Y, Giovannini M (2004) Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 64(10):3718\u20133724","journal-title":"Cancer Res"},{"issue":"2","key":"2567_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1700\/1491.16411","volume":"100","author":"J Wagner","year":"2014","unstructured":"Wagner J, Welzel T, Habermehl D, Debus J, Combs SE (2014) Radiotherapy in patients with vestibular schwannoma and neurofibromatosis type 2: clinical results and review of the literature. Tumori 100(2):189\u2013194. doi: 10.1700\/1491.16411","journal-title":"Tumori"},{"issue":"2","key":"2567_CR48","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/cncr.24036","volume":"115","author":"JH Phi","year":"2009","unstructured":"Phi JH, Kim DG, Chung HT, Lee J, Paek SH, Jung HW (2009) Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation. Cancer 115(2):390\u2013398. doi: 10.1002\/cncr.24036","journal-title":"Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-017-2567-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2567-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2567-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T09:57:47Z","timestamp":1659261467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-017-2567-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,22]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["2567"],"URL":"https:\/\/doi.org\/10.1007\/s11060-017-2567-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,22]]}}}